Reuters logo
BRIEF-Concert Pharmaceuticals says announced an unexpected delay in initiation of CTP-543 phase 2a trial
April 5, 2017 / 12:33 PM / 7 months ago

BRIEF-Concert Pharmaceuticals says announced an unexpected delay in initiation of CTP-543 phase 2a trial

April 5 (Reuters) - Concert Pharmaceuticals Inc

* Concert Pharmaceuticals Inc - announced an unexpected delay in initiation of CTP-543 phase 2a trial for alopecia areata

* Concert Pharmaceuticals Inc - concert is investigating issue and is working to remedy situation

* Concert Pharmaceuticals Inc - expects to initiate and enroll trial in 2017 with topline data expected in Q1 of 2018

* Concert Pharmaceuticals - delay in initiation of CTP-543 phase 2a trial for alopecia areata due to a late emerging clinical tablet appearance issue Source text for Eikon: (bit.ly/2oCuCfv) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below